Concluded Case

AWARD 11, DULAGLUTIDE GLP1 RA, GREATER REDUCTIONS IN HBA1C & WEIGHT

Desr my friends and fellow Colleagues, Here is an update on Dulaglutide, GLP1 Receptor Agonist. Higher dulaglutide dose shows greater reductions in HbA1c, weight – AWARD 11 Trial. https://www.empr.com/home/news/drugs-in-the-pipeline/higher-dulaglutide-dose-hba1c-type-2-diabetes-trulicity/ (Accession Date: May 25, 2020) Regards and thanks, Dr Sepuri Krishna Mohan.

3 Likes

LikeAnswersShare
Concluded answer
Wonderful update as usual Dr Mohan. Dulaglutide is a once a week, sub cutaneous injectable GLP1 RA Original Research Molecule of Eli Lilly Company. The dosage is 0.75 mg & 1.5 mg prefilled syringe with a needle attached and doesn't require any dose measurements. We have been seeing from AWARD 1 Trial to AWARD 11. If Dulaglutide is used in the dose of 3 mg or 4.5 mg once a week SC injection, shows greater reduction in both HbA1c and Weight. It has got very favourable effects in CV outcomes hence becomes drug of choice for T2DM as an adjunct therapy to Diet, Exercise and Metformin. Recent ESC/EASD & AHA/ACE/AACE/ADA Guidelines say that either SGLT2 Inhibitors or GLP1 Analogues are the first drugs of choice in T2DM naive patients or otherwise with ir without Metformin with either established ASCVD or at risk of ASCVD. But the only concern in our country or low resource setting countries like developing or underdeveloped is the COST & AFFORDABILITY. Otherwise it's a wonderful molecule with proven CV safety and Weight Reduction in T2DM, especially the obese or morbidly obese patients where cost and affordability are not a problem. Thanks again Dr Mohan for wonderful update on AWARD 11.
All Answers
Wonderful update as usual Dr Mohan. Dulaglutide is a once a week, sub cutaneous injectable GLP1 RA Original Research Molecule of Eli Lilly Company. The dosage is 0.75 mg & 1.5 mg prefilled syringe with a needle attached and doesn't require any dose measurements. We have been seeing from AWARD 1 Trial to AWARD 11. If Dulaglutide is used in the dose of 3 mg or 4.5 mg once a week SC injection, shows greater reduction in both HbA1c and Weight. It has got very favourable effects in CV outcomes hence becomes drug of choice for T2DM as an adjunct therapy to Diet, Exercise and Metformin. Recent ESC/EASD & AHA/ACE/AACE/ADA Guidelines say that either SGLT2 Inhibitors or GLP1 Analogues are the first drugs of choice in T2DM naive patients or otherwise with ir without Metformin with either established ASCVD or at risk of ASCVD. But the only concern in our country or low resource setting countries like developing or underdeveloped is the COST & AFFORDABILITY. Otherwise it's a wonderful molecule with proven CV safety and Weight Reduction in T2DM, especially the obese or morbidly obese patients where cost and affordability are not a problem. Thanks again Dr Mohan for wonderful update on AWARD 11.
Wonderful summary of AWARD 11 Dr Devi.
0

View 1 other reply

Nice information sir
Thank you doctor
0